Alpha-1 抗胰蛋白酶缺乏症市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、給藥途徑、配銷通路、地區和競爭細分，2020-2030 年）

2024 年全球 Alpha-1 抗胰蛋白酶缺乏症市場價值為 22.4 億美元，預計到 2030 年將達到 35.3 億美元，預測期內的複合年成長率為 7.82%。 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1 抗胰蛋白酶缺乏症）是一種影響肺部和肝臟的罕見遺傳性疾病。它是由 alpha-1 抗胰蛋白酶缺乏引起的，從而增加肺部和肝臟疾病的風險。雖然 Alpha-1 抗胰蛋白酶缺乏症被認為是一種罕見疾病，但它對患者的生活品質和醫療保健系統的影響卻很大。隨著研究的進展和認知的提高，Alpha-1 抗胰蛋白酶缺乏症市場正在轉變，既帶來挑戰也帶來機會。 Alpha-1 抗胰蛋白酶是由肝臟產生的一種蛋白質，在保護肺部免受發炎期間釋放的酵素造成的損害方面起著至關重要的作用。患有α-1抗胰蛋白酶缺乏症的個體，其基因突變會導致一種錯誤折疊的蛋白質的產生，這種蛋白質會在肝臟中積聚，而不是被釋放到血液中。這種缺陷導致患者更容易患上肺部疾病，例如慢性阻塞性肺病 (COPD)，以及肝臟疾病，例如肝硬化。

由於 Alpha-1 抗胰蛋白酶缺乏症 (Alpha-1 Antitrypsin Deficiency Disease) 的罕見性，該疾病的市場規模相對較小。然而，該疾病正受到研究人員、製藥公司和醫療保健提供者的關注。該市場由幾家專注於診斷、治療和療法的關鍵參與者組成。這些公司專注於開發旨在解決潛在缺陷並控制相關併發症的療法。生物技術、基因組學和個人化醫療的進步，使得針對 Alpha-1 抗胰蛋白酶缺乏症的療法更具針對性、更有效的開發成為可能。這些創新有可能徹底改變治療方法，從而改善患者的治療效果並提高生活品質。政府措施和增加的研究資金在推動全球 Alpha-1 抗胰蛋白酶缺乏症市場成長方面發揮了關鍵作用。隨著人們對 Alpha-1 抗胰蛋白酶缺乏症等罕見疾病的認知不斷提高，各國政府和監管機構正在訂定政策和項目，以支持此類疾病的研究、診斷和治療發展。研究項目、臨床試驗和患者支持計劃的資金吸引了製藥公司和研究人員的關注，從而加速了該領域的進步。

關鍵市場促進因素

患者人數不斷成長

主要市場挑戰

診斷不足及誤診

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球 α-1 抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（α-1蛋白酶抑制劑、支氣管擴張劑、皮質類固醇、氧氣療法）
  • 依給藥途徑（注射、口服、吸入）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按產品
  • 依給藥途徑
  • 按配銷通路
  • 按地區

第6章：北美 α-1 抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測

第7章：歐洲 Alpha-1 抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測

第 8 章：亞太地區 α-1 抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測

第9章：南美洲α-1抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測

第 10 章：中東與非洲 Alpha-1 抗胰蛋白酶缺乏症市場展望

• 市場規模和預測
• 市場佔有率和預測

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：競爭格局

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols SA
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

第 14 章：策略建議

第15章調查會社について,免責事項

The global Alpha-1 Antitrypsin Deficiency Disease Market was valued at USD 2.24 billion in 2024 and is expected to reach USD 3.53 billion by 2030, growing at a CAGR of 7.82% during the forecast period. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency in the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. While Alpha-1 Antitrypsin Deficiency Disease is considered a rare disease, its impact on patients' quality of life and healthcare systems is significant. As research advances and awareness grows, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing transformations, offering both challenges and opportunities. Alpha-1 antitrypsin is a protein produced by the liver that plays a crucial role in protecting the lungs from damage caused by enzymes released during inflammation. In individuals with Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to the production of a misfolded protein that accumulates in the liver rather than being released into the bloodstream. This deficiency results in a higher susceptibility to lung diseases like chronic obstructive pulmonary disease (COPD) and liver diseases like cirrhosis.

The Alpha-1 Antitrypsin Deficiency Disease market is relatively small due to the rare nature of the disease. However, it is gaining attention from researchers, pharmaceutical companies, and healthcare providers. The market is characterized by a few key players specializing in diagnostics, treatments, and therapies. These companies focus on developing therapies that aim to address the underlying deficiency and manage associated complications. Advancements in biotechnology, genomics, and personalized medicine have enabled the development of more targeted and effective therapies for Alpha-1 Antitrypsin Deficiency Disease. These innovations have the potential to revolutionize treatment approaches, leading to better patient outcomes and improved quality of life. Government initiatives and increased research funding have played a pivotal role in driving the growth of the global Alpha-1 Antitrypsin Deficiency Disease market. As awareness about rare diseases like Alpha-1 Antitrypsin Deficiency Disease increases, governments and regulatory bodies are introducing policies and programs to support research, diagnosis, and treatment development for such conditions. Funding for research projects, clinical trials, and patient support programs have attracted the attention of pharmaceutical companies and researchers, leading to accelerated advancements in the field.

Key Market Drivers

Growing Patient Population

Alpha-1 Antitrypsin Deficiency (AATD) is a rare but serious genetic disorder that impairs lung and liver function, primarily due to insufficient levels of the alpha-1 antitrypsin protein. Though historically underdiagnosed, awareness surrounding AATD is steadily increasing. According to the Alpha-1 Foundation, it is estimated that 1 in 2,500 individuals in the United States may have the condition, but only a fraction have been properly diagnosed. This growing recognition is leading to a larger identified patient pool, highlighting the urgent need for improved diagnostic infrastructure and targeted therapies to manage and treat the condition effectively.

Misdiagnosis remains a significant hurdle in the clinical journey of many AATD patients. Because symptoms such as shortness of breath and wheezing overlap with more common conditions like asthma or chronic obstructive pulmonary disease (COPD), proper diagnosis is often delayed. However, with the rollout of improved diagnostic tools and broader genetic testing programs, correct identification is becoming more feasible. A 2023 study indicated that over 60% of newly confirmed AATD cases were initially misdiagnosed, underscoring the critical importance of awareness campaigns and early screening initiatives in catching the disease sooner and enabling timely treatment interventions.

As the pool of diagnosed patients expands, so does the interest from pharmaceutical companies and researchers to develop targeted treatments. Enzyme replacement therapies (ERTs), which replenish the deficient alpha-1 antitrypsin protein, have become a cornerstone in managing AATD. These therapies help reduce lung inflammation and preserve respiratory function. At the same time, advancements in gene therapy and RNA-based treatments are providing hope for long-term or even curative solutions. The clinical pipeline is expanding rapidly, with a number of therapies in various stages of development, targeting both symptomatic relief and genetic correction.

The availability of multiple therapeutic options is not only enhancing patient care but also creating new opportunities in the healthcare market. This is especially true as physicians are becoming more equipped to tailor treatments to the severity and progression of the disease. Increasing participation in patient registries and real-world evidence collection are further contributing to a deeper understanding of AATD and enabling personalized medicine approaches. As more individuals are diagnosed and gain access to effective care, the growing patient population will continue to be a central driver in the advancement of the Alpha-1 Antitrypsin Deficiency Disease treatment landscape.

Key Market Challenges

Under diagnosis and Misdiagnosis

One of the most pressing challenges in the Alpha-1 Antitrypsin Deficiency (AATD) market is the high rate of underdiagnosis. Due to the rarity of the condition and low awareness among both patients and primary care providers, AATD often goes undetected for years. Many individuals remain asymptomatic until the disease has significantly progressed, making early intervention difficult. Even when symptoms appear such as shortness of breath or recurrent respiratory infections-they are frequently attributed to more common conditions like asthma or chronic obstructive pulmonary disease (COPD). This diagnostic delay not only worsens patient outcomes but also limits the window of opportunity for implementing effective treatments and managing disease progression proactively.

Misdiagnosis compounds the challenge, as individuals with AATD are often treated incorrectly for unrelated respiratory or liver conditions. These inappropriate treatments can lead to ineffective care, increased healthcare costs, and a delay in addressing the root genetic cause of the symptoms. For example, corticosteroids may be prescribed under the assumption of asthma, when in fact, AATD-related lung damage requires enzyme replacement or targeted therapy. Moreover, many clinicians lack familiarity with the specific diagnostic tests needed such as serum AAT levels and genetic testing-leading to oversight in patient evaluation. This systemic issue highlights the need for increased physician education, standardized screening protocols, and public awareness campaigns to ensure timely, accurate diagnosis and improve long-term patient care.

Key Market Trends

Technological Advancements

Technological strides in genetic screening have enabled early detection of Alpha-1 Antitrypsin Deficiency Disease. Genetic tests can identify specific mutations associated with the deficiency, allowing healthcare providers to diagnose individuals even before symptoms manifest. This proactive approach empowers patients to make informed decisions about their health and lifestyle, potentially mitigating the severity of complications. Further, the advent of precision medicine, which tailors treatment plans based on an individual's genetic makeup, is revolutionizing Alpha-1 Antitrypsin Deficiency Disease management. With insights gleaned from genetic testing, medical professionals can design personalized interventions, optimizing treatment efficacy and minimizing adverse effects. The emergence of gene therapy and gene editing technologies is creating exciting avenues for treating genetic disorders like Alpha-1 Antitrypsin Deficiency Disease. Researchers are exploring ways to replace or correct the mutated gene responsible for Alpha-1 Antitrypsin Deficiency Disease, potentially restoring normal protein production. These innovative approaches hold the promise of not just managing the symptoms but addressing the root cause of the condition. Telemedicine has become an essential tool in managing chronic diseases. Patients with Alpha-1 Antitrypsin Deficiency Disease can now access remote consultations with specialists, receive real-time guidance, and monitor their health using wearable devices. This facilitates regular check-ins and timely interventions, ultimately enhancing the overall quality of care. As the technological landscape continues to evolve, the prospects for individuals with Alpha-1 Antitrypsin Deficiency are looking increasingly optimistic. Innovative therapies, precise diagnostics, and personalized treatment plans are reshaping the Alpha-1 Antitrypsin Deficiency Disease landscape, offering renewed hope to patients and their families. However, challenges such as ethical considerations, accessibility, and cost-effectiveness must also be addressed to ensure that the benefits of these technological advancements are equitably distributed. The application of big data analytics and artificial intelligence (AI) in medical research has expedited the identification of potential drug candidates. AI algorithms can analyze massive datasets to pinpoint molecules that could modulate AAT production or function, expediting the drug discovery process.

Key Market Players

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

Report Scope:

In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

• Alpha-1 Proteinase Inhibitor
• Bronchodilato
• Corticosteroid
• Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

• Injection
• Oral
• Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

• Hospitals Pharmacy
• Retail Pharmacies
• Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
  • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
    • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel
    • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
    • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Product
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
    • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
    • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
    • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
    • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
    • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
    • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
    • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
    • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
    • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
    • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
    • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
    • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
    • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Shire plc
• 13.2. GlaxoSmithKline plc
• 13.3. CSL Behring
• 13.4. AstraZeneca Plc.
• 13.5. Grifols S.A.
• 13.6. Teva Pharmaceutical Industries
• 13.7. Boehringer Ingelheim International GmbH
• 13.8. Kamada Pharmaceuticals
• 13.9. Pfizer Inc.
• 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer